Peter Campbell, a leader in the new field of somatic genomics, has been named chief scientific officer of Quotient Therapeutics Ltd, a company launched in November 2023 to discover therapeutics across a broad range of diseases. It aims to study the genetic variation and evolution of cells inside the human body. Dr Campbell, who is the company’s academic co-founder, was previously head of cancer, ageing, and somatic mutation at the Wellcome Sanger Institute in the UK. He was awarded the UK Royal Society’s Darwin Medal in 2023 and before that, elected to the US National Academy of Medicine. Dr Campbell received his PhD from the University of Cambridge and completed his postdoctoral fellowship at the Wellcome Sanger Institute, both in the UK.
Quotient Therapeutics announced the appointment on 7 August 2024.
Copyright 2024 Evernow Publishing Ltd.